Please Wait
Applying Filters...
menu
    • menu
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Lee Pharma Ltd: Global supplier of certified APIs and formulations, driven by innovation and regulatory excellence.

    Virtual Booth

    Contact Supplier

    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    Ethypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the world.

    Virtual Booth

    Contact Supplier

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    Menu

    LY-2940094

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    BlackThorn Enrolls First Patient in Ph2a Study of Lead Compound, BTRX-246040
    BlackThorn Enrolls First Patient in Ph2a Study of Lead Compound, BTRX-246040

    24 Jul 2017

    // PRESS RELEASE

    http://www.blackthornrx.com/blackthorn-therapeutics-enrolls-first-patient-in-phase-2a-study-of-lead-compound-btrx-246040-in-major-depressive-disorder/

    PRESS RELEASE
    24 Jul 2017
    Share Share
    BlackThorn Therapeutics Secures $14 Million in Series A Extension Financing
    BlackThorn Therapeutics Secures $14 Million in Series A Extension Financing

    05 Jan 2017

    // PRESS RELEASE

    http://www.blackthornrx.com/blackthorn-therapeutics-secures-14-million-in-series-a-extension-financing/

    PRESS RELEASE
    05 Jan 2017
    Share Share